JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

Начало・Списък с акции・Alkermes PLC

Alkermes PLC

Отворен

СекторЗдравеопазване

30.17 -3.98

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

29.88

Максимум

31.32

Ключови измерители
By Trading Economics
Приходи	65M 87M
Продажби	84M 391M
P/E Средно за сектора	14.613 37.461
Марж на печалбата	22.295
Служители	1,800
EBITDA	99M 113M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+29.09% upside

Дивиденти
By Dow Jones
Следващи печалби	28.10.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	802M 5.1B
Предишно отваряне	34.15
Предишно затваряне	30.17

Настроения в новините

By Acuity

50%

168 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

27.95 / 30.91 Подкрепа & съпротива

Alkermes PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.10.2025 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22.10.2025 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22.10.2025 г., 21:20 ч. UTC

Печалби

Correction to IBM 3Q Sales Jump Article

22.10.2025 г., 20:57 ч. UTC

Печалби

SAP Posts Higher 3Q Revenue, Operating Profit

22.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22.10.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22.10.2025 г., 23:15 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22.10.2025 г., 22:28 ч. UTC

Пазарно говорене

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22.10.2025 г., 22:02 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22.10.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22.10.2025 г., 21:58 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22.10.2025 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22.10.2025 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22.10.2025 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22.10.2025 г., 21:47 ч. UTC

Печалби

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22.10.2025 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22.10.2025 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22.10.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22.10.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22.10.2025 г., 21:28 ч. UTC

Пазарно говорене

Печалби

Correction to Alcoa Tariff Market Talk

22.10.2025 г., 21:25 ч. UTC

Печалби

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22.10.2025 г., 21:17 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22.10.2025 г., 21:09 ч. UTC

Пазарно говорене

Печалби

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22.10.2025 г., 21:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

22.10.2025 г., 20:59 ч. UTC

Печалби

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22.10.2025 г., 20:51 ч. UTC

Печалби

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.10.2025 г., 20:44 ч. UTC

Печалби

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Сравнение с други в отрасъла

Ценова промяна

Alkermes PLC Прогноза

Ценова цел

By TipRanks

29.09% нагоре

12-месечна прогноза

Среден 40.6 USD 29.09%

Висок 47 USD

Нисък 33 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Alkermes PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Alkermes PLC през последните 3 месеца.

Техническа оценка

By Trading Central

27.95 / 30.91Подкрепа & съпротива

Bullish events outweigh bearish events.

All events are bearish.

All events are bullish.

Настроение

By Acuity

168 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.